The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)-Reference-Cited by-同舟云学术

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Published:2022-09-01 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Hizal Mutlu^ORCID,Bilgin Burak,Paksoy Nail,Atcı Muhammed Mustafa,Kahraman Seda,Kılıçkap Saadettin,Güven Deniz Can,Keskinkılıç Merve,Ayhan Murat,Eren Önder,Mustafayev Fatma Nihan Akkoç,Yaman Şebnem,Bayram Ertuğrul,Ertürk İsmail,Özcan Erkan,Korkmaz Mustafa,Akagündüz Baran,Erdem Dilek,Telli Tuğba Akın,Aksoy Asude,Üskent Necdet,Baytemür Naziyet Köse,Gülmez Ahmet,Aydın Dinçer,Şakalar Teoman,Arak Hacı,Tatlı Ali Murat,Ergün Yakup,Ak Naziye,Ünal Çağlar,Özgün Mehmet Alpaslan,Yalçın Bülent,Öztop İlhan,Algın Efnan,Sakin Abdullah,Aydıner Adnan,Yumuk Perran Fulden,Şendur Mehmet Ali Nahit

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04252-2.pdf

Reference15 articles.

1. Bilgin B, Şendur MAN, Yücel Ş, Hizal M, Güner G, Akyürek N et al (2021) The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. J Cancer Res Clin Oncol 147(9):2637–2643

2. He Y, Gong R, Sun LY, Zhang ZC, Liu XY, Shao Q et al (2019) The percentage of anaplastic lymphoma kinase-positive tumor cells has clinical implications for patients with non-small cell lung cancer. Genet Test Mol Biomark 23(8):589–597

3. Jiang F, Wang C, Yang P, Sun P, Liu J (2021) Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study. World J Surg Oncol 19(1):278

4. Koh Y, Kim DW, Kim TM, Lee SH, Jeon YK, Chung DH et al (2011) Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 6(5):905–912

5. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med 363(18):1693–1703

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?;Frontiers in Oncology;2024-06-18

2. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms;Frontiers in Pharmacology;2023-10-25

3. Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report;Medicine International;2023-10-17

4. Low level ALK FISH positive results should be approached with caution and confirmed by an orthogonal method;Translational Lung Cancer Research;2023-07